Skip to content
AnalystLens

Exelixis Quarterly Report for Q3 Ended Oct 3, 2025

Filing Date
Filed November 4, 2025
Period End
October 3, 2025
Security
EXEL
One revenue dollarkept$0.32
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · Jun ’24Jun ’24

Summary

Summary of the 10-Q filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported third-quarter 2025 total revenues of $597.8 milliona, up from $539.5 million a year earlier, driven by net product revenues of $542.9 million, which rose from $478.1 million.

Net product revenues were primarily CABOMETYX, at $539.9 millionb for the quarter. Collaboration revenues declined to $54.8 million from $61.5 million, as license revenues fell with fewer milestones. Income from operations was $236.5 million, versus $136.1 million a year earlier, and net income was $193.6 million, or $0.69 per diluted share, compared with $118.0 million, or $0.40 per diluted share.

The quarter included $19.8 millionc in restructuring expenses tied to the 2025 Plan, which closed the King of Prussia, Pennsylvania office. For the nine months ended September 30, 2025, net cash from operating activities was $550.8 million. Cash, cash equivalents and marketable securities totaled $1.6 billion, down from $1.7 billion at December 31, 2024, mainly because of $689.9 million in share repurchase payments.

As of September 30, 2025, $104.7 milliond remained under existing repurchase authorizations, and in October 2025 the board authorized an additional $750.0 million through December 31, 2026. Management states that current resources should fund operations for at least 12 months. The filing highlights pending generic challenges to CABOMETYX, including ANDA litigation with MSN, Sun, and Azurity, with trial scheduled for November 2, 2026.

Exelixis settled with Biocon, which will be licensed to market a generic version in the U.S. beginning January 1, 2031. The company also reported positive top-line results from the STELLAR-303 phase 3 trial of zanzalintinib, and it intends to file a New Drug Application by the end of 2025, subject to the availability of government services.

Key Highlights

  1. Total revenues of $597.8 million in Q3 2025, up from $539.5 million, with net product revenues of $542.9 million, up from $478.1 million.
  2. Net income of $193.6 million, or $0.69 per diluted share, versus $118.0 million, or $0.40 per diluted share, in Q3 2024.
  3. Collaboration revenues fell to $54.8 million from $61.5 million, and license revenues declined to $56.2 million from $60.2 million.
  4. Restructuring expenses of $19.8 million in Q3 2025 related to the 2025 Plan to reorganize the workforce and close the King of Prussia office.
  5. Repurchases of common stock totaled $689.9 million in cash for the nine months ended September 30, 2025, and an additional $750.0 million repurchase authorization was approved in October 2025.
  6. Cash, cash equivalents and marketable securities totaled $1.6 billion as of September 30, 2025, compared with $1.7 billion at December 31, 2024.
  7. A Biocon settlement will allow generic CABOMETYX in the U.S. beginning January 1, 2031, while MSN, Sun, and Azurity ANDA litigation is scheduled for trial on November 2, 2026.

Follow one dollar

Of each $1.00 of revenue in Q3 FY2026, Exelixis kept $0.32.

  1. Revenue$597.8M100.0%
  2. Cost of revenue−$18.6M3.1%
  3. Gross profit$579.2M96.9%
  4. Operating costs−$342.6M57.3%
  5. Operating income$236.5M39.6%
  6. Interest, other & tax−$43.0M7.2%
  7. Net income$193.6M32.4%
Computed from 10-QQ3 FY2026filed November 4, 2025Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q3 FY2026 against Q3 FY2025

Line itemQ3 FY2026Q3 FY2025Change
Revenue$597.75M$539.54M+10.8%
Cost of Revenue$18.57M$17.33M+7.2%
Gross Profit$579.18M$522.21M+10.9%
R&D Expenses$199.16M$222.57M−10.5%
SG&A Expenses$123.66M$111.80M+10.6%
Operating Expenses$361.21M$403.47M−10.5%
Operating Income$236.54M$136.07M+73.8%
Net Income$193.58M$117.97M+64.1%
EPS (Basic)$0.72$0.41+75.6%
EPS (Diluted)$0.69$0.40+72.5%
Shares Outstanding (Basic)268.42M285.62M−6.0%
Shares Outstanding (Diluted)278.54M291.48M−4.4%

Frequently Asked Questions

  1. How did Exelixis perform financially in the third quarter of 2025?

    Total revenues were $597.8 million, compared with $539.5 million in the third quarter of 2024. Net income was $193.6 million, or $0.69 per diluted share, compared with $118.0 million, or $0.40 per diluted share, a year earlier. Income from operations was $236.5 million, compared with $136.1 million.

  2. What drove the growth in revenue?

    The filing attributes the growth in net product revenues to a 17% increase in CABOMETYX units sold in the quarter, reflecting demand for the combination with nivolumab in first-line advanced RCC and for previously treated advanced NET. Collaboration revenues declined, partly due to lower license revenues from fewer milestones.

  3. What are the main legal risks to CABOMETYX revenue?

    Several companies have filed ANDAs or a 505(b)(2) NDA for generic versions of CABOMETYX. Exelixis has sued MSN, Sun, and Azurity, and these cases have been consolidated with trial scheduled for November 2, 2026. Exelixis settled with Biocon, which will be licensed to market a generic version beginning January 1, 2031. The filing states that approval and launch of any generic could significantly decrease U.S. CABOMETYX revenues.

  4. How much capital does Exelixis have, and how is it being returned to shareholders?

    Cash, cash equivalents and marketable securities totaled $1.6 billion at September 30, 2025, down from $1.7 billion at year-end 2024. Stock repurchases used $689.9 million in cash during the first nine months of 2025. Approximately $104.7 million remained available under existing programs as of September 30, 2025, and the board added $750.0 million of authorization in October 2025.

  5. What is the status of the zanzalintinib program?

    The STELLAR-303 phase 3 trial of zanzalintinib plus atezolizumab versus regorafenib in metastatic colorectal cancer showed a statistically significant improvement in overall survival in the intention-to-treat population. Exelixis plans to submit a New Drug Application by the end of 2025, subject to FDA availability during the federal government shutdown. The STELLAR-304 trial's top-line results are expected in the second half of 2026.